SAN PEDRO, Calif.–Celprogen Inc., a leader in the Stem Cell Research and Therapeutics industry for the development of stem cell technologies for regenerative medicine, today announced that they have successfully isolated and propagated Human Triple Negative Breast cancer stem cells. Breast Cancer is most common malignancy among women in developed countries, affecting more than a million women per year worldwide. Of these, Triple Negative Breast Carcinoma represents 10-17%.

Celprogen’s Breast Cancer Stem Cells are characterized by estrogen, progesterone and HER2 receptor negative and are very aggressive tumors with poor prognosis. The Triple Negative Breast Cancer Parental and Cancer Stem cells together with their high through put cell based assay kits provides basic science research and drug discovery programs to screen and design novel drug candidates for treatment of patients with this type of cancer.

Celprogen provides Cancer Stem Cell Tissue culture system which includes cells, pre-coated flasks with extracellular matrix and Medium for growth and proliferation of these cells. Celprogen also offers the Cancer Stem Cell characterization cell based assay system for screen novel drug candidates for finding treatments for Breast Cancer Patients.

About Celprogen Inc.

Celprogen Inc. is a global Stem Cell Research & Therapeutics company which is developing a proprietary portfolio of unique cancer therapeutics products and life science research tools that includes stem cell technologies for regenerative medicine, as well as bio-engineering products for tissue & organ transplants. Headquartered in San Pedro, California, Celprogen is committed to the research, development, and manufacture of quality Stem Cell, Cancer Stem Cell and Primary Cell Culture products to serve our global community. Additional information about Celprogen is available at https://www.celprogen.com.